对受监管市场中基于大麻素的产品标签准确性的系统评价：标签上的成分与产品中的成分相符吗？
A systematic review of the label accuracy of cannabinoid-based products in regulated markets: is what's on the label what's in the product?
作者信息
Oldfield Karen, Ryan John, Doppen Marjan, Kung Stacey, Braithwaite Irene, Newton-Howes Giles
机构信息
Medical Research Institute of New Zealand, Wellington, New Zealand.
Victoria University, Wellington, New Zealand.
出版信息
Australas Psychiatry. 2021 Feb;29(1):88-96. doi: 10.1177/1039856220965334. Epub 2020 Nov 11.
OBJECTIVES
To review the literature regarding label accuracy and contamination of medical cannabinoid-based products.
METHODS
A systematic review with meta-analysis following PRISMA guidelines. This study is registered with PROSPERO (CRD42019131565).
RESULTS
Five studies reported label accuracy data ranging between 17% and 86%. Four studies reported contaminants, including pesticides, solvents and AB-FUBINACA. Meta-analysis was limited to the proportion of pesticide-contaminated samples found in two studies (0.25 (95% CI [0.10, 0.40])) and displayed significant heterogeneity.
CONCLUSIONS
Label inaccuracies and contaminants are found across a spectrum of cannabinoid-based products. The review highlights the paucity and heterogeneity of research relating to cannabinoid-based products in light of changing global legislation. Further robust research is required to support ongoing pharmacovigilance and patient safety.
目的
回顾关于基于医用大麻素产品的标签准确性和污染情况的文献。
方法
按照PRISMA指南进行系统评价并荟萃分析。本研究已在PROSPERO（CRD42019131565）注册。
结果
五项研究报告了标签准确性数据，范围在17%至86%之间。四项研究报告了污染物情况，包括农药、溶剂和AB - FUBINACA。荟萃分析仅限于两项研究中发现的受农药污染样本的比例（0.25（95%可信区间[0.10, 0.40]）），且显示出显著的异质性。
结论
在各类基于大麻素的产品中均发现标签不准确和存在污染物的情况。鉴于全球法规不断变化，该综述凸显了与基于大麻素产品相关研究的匮乏和异质性。需要进一步开展有力研究以支持持续的药物警戒和患者安全。
Zotero 插件